MedDataX Logo

Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison

NCT01379677 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2014-05-14

No results posted yet for this study

Summary

The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82 PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).

Conditions

  • Coronary Artery Disease

Interventions

DRUG

Rubidium-82

Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use

DRUG

Sestamibi. reconstitution with sodium pertechnetate (99mTc)

Maximum dose allowed per injection: 1000 MBq Intravenous Use

Sponsors & Collaborators

  • Advanced Accelerator Applications

    lead INDUSTRY

Principal Investigators

  • Leon Menezes, Dr. · University College Hospital London NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United Kingdom

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01379677 on ClinicalTrials.gov